» Articles » PMID: 19398470

Protective Ischaemia in Patients: Preconditioning and Postconditioning

Overview
Journal Cardiovasc Res
Date 2009 Apr 29
PMID 19398470
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Infarct size can be limited by reducing the determinants of infarct size or increasing collateral blood flow by treatment initiated before the ischaemic event. Reperfusion is the definitive treatment for permanently reducing infarct size and restoring some degree of contractile function to the affected myocardium. Innate survival mechanisms in the heart can be stimulated by short, non-lethal periods of ischaemia and reperfusion, applied either before or after the ischaemic event. Preconditioning, a series of transient intervals of ischaemia and reperfusion applied before the lethal 'index' ischaemic event, sets in motion molecular and cellular mechanisms that increase cardiomyocyte survival to a degree that had not hitherto been seen before. The cardioprotective ischaemic-reperfusion protocol applied at onset of reperfusion, termed 'postconditioning' (Postcon), is also associated with significant cardioprotection that can be applied at the point of reperfusion treatment in the catheterization laboratory or operating room. Both preconditioning and Postcon have been successfully applied to the clinical setting and have been found to reduce infarct size and other attributes of post-ischaemic injury. This review will summarize the physiological preclinical data on preconditioning and Postcon that are relevant to their translation to clinical therapeutics and treatment.

Citing Articles

Ischemic preconditioning modulates the DNA methylation process of the rat heart to provide tolerance to withstand ischemia reperfusion injury and its associated mitochondrial dysfunction.

Boovarahan S, Kurian G 3 Biotech. 2024; 14(4):121.

PMID: 38550905 PMC: 10965879. DOI: 10.1007/s13205-024-03965-0.


Salvianolic acids and its potential for cardio-protection against myocardial ischemic reperfusion injury in diabetes.

Jiang Y, Cai Y, Han R, Xu Y, Xia Z, Xia W Front Endocrinol (Lausanne). 2024; 14:1322474.

PMID: 38283744 PMC: 10811029. DOI: 10.3389/fendo.2023.1322474.


Renal vascular responses to angiotensin II infusion in two kidneys-one clip hypertensive rats under partial ischemia/reperfusion with and without ischemia preconditioning: the roles of AT1R blockade and co-blockades of AT1R and MasR.

Karimi F, Nematbakhsh M Res Pharm Sci. 2023; 18(4):392-403.

PMID: 37614612 PMC: 10443668. DOI: 10.4103/1735-5362.378086.


Long-term inorganic nitrate administration protects against myocardial ischemia-reperfusion injury in female rats.

Yassaghi Y, Jeddi S, Yousefzadeh N, Kashfi K, Ghasemi A BMC Cardiovasc Disord. 2023; 23(1):411.

PMID: 37605135 PMC: 10441752. DOI: 10.1186/s12872-023-03425-2.


Cardio-Protective Role of a Gut Hormone Obestatin: A Narrative Review.

Bora R, Prasad R, Khatib M Cureus. 2023; 15(4):e37972.

PMID: 37223200 PMC: 10202687. DOI: 10.7759/cureus.37972.


References
1.
Halestrap A, Kerr P, Javadov S, Woodfield K . Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta. 1998; 1366(1-2):79-94. DOI: 10.1016/s0005-2728(98)00122-4. View

2.
Caputo M, Dihmis W, Bryan A, Suleiman M, Angelini G . Warm blood hyperkalaemic reperfusion ('hot shot') prevents myocardial substrate derangement in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg. 1998; 13(5):559-64. DOI: 10.1016/s1010-7940(98)00056-6. View

3.
OLAFSSON B, Forman M, Puett D, Pou A, Cates C, FRIESINGER G . Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 1987; 76(5):1135-45. DOI: 10.1161/01.cir.76.5.1135. View

4.
Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D . Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res. 2008; 104(1):15-8. DOI: 10.1161/CIRCRESAHA.108.186429. View

5.
Wall T, Sheehy R, Hartman J . Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994; 270(2):681-9. View